Sandbox Reserved 1165
From Proteopedia
| Line 25: | Line 25: | ||
Many of the residues that are in direct contact with the glucagon molecule are charged or are polar. | Many of the residues that are in direct contact with the glucagon molecule are charged or are polar. | ||
| - | There are also any bulk resides on glucagon that support the bulky resides on the GCGR. These residues are located within the binding pocket of the 7TM. There are specific amino acid interactions that hold the helices of the 7TM in the conformation that maximizes affinity, this includes a disulfide bond between Cys 294 and Cys 224 that serves to hold the ECL1 and ECL2 in the proper orientation.Also, the salt bridges between Glu 406, Arg 173, and Arg 346 that hold the conformation of affinity. Alpha helical structure of the stalk is imperative to the affinity and binding of the glucagon. | + | There are also any bulk resides on glucagon that support the bulky resides on the GCGR. These residues are located within the binding pocket of the 7TM. There are specific amino acid interactions that hold the helices of the 7TM in the conformation that maximizes affinity, this includes a disulfide bond between Cys 294 and Cys 224 that serves to hold the ECL1 and ECL2 in the proper orientation. Also, the salt bridges between Glu 406, Arg 173, and Arg 346 that hold the conformation of affinity. Alpha helical structure of the stalk is imperative to the affinity and binding of the glucagon. |
Revision as of 13:21, 22 March 2016
[[Image:]]
| This Sandbox is Reserved from Jan 11 through August 12, 2016 for use in the course CH462 Central Metabolism taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1160 through Sandbox Reserved 1184. |
To get started:
More help: Help:Editing |
Human Glucagon Class B G Protein-Coupled Receptors (GPCRs)
| |||||||||||
Clinical Relevancy
Of the fifteen human class B GPCRs, eight have been identified as potential drug target[2]. Therapeutic agents have been created from the peptides themselves within this protein, but overall pharmaceutical companies have had difficulty creating agents that act on family B GPCRS. There is an outward appearance and inherent flexibility in the class B GCGR 7TM because of conserved hydrogen bonds that flank a glycine residue, and this structure along with the ECD and its role of interactions on the extracellular side of receptors may provide evidence to how class B receptors adjust its conformational spectra for various receptors. Researchers hope to show how these conformations can be utilized in potential treatments of a wide array disorders.
References
- ↑ Hollenstein K, de Graaf C, Bortolato A, Wang MW, Marshall FH, Stevens RC. Insights into the structure of class B GPCRs. Trends Pharmacol Sci. 2014 Jan;35(1):12-22. doi: 10.1016/j.tips.2013.11.001. Epub, 2013 Dec 18. PMID:24359917 doi:http://dx.doi.org/10.1016/j.tips.2013.11.001
- ↑ Bortolato A, Dore AS, Hollenstein K, Tehan BG, Mason JS, Marshall FH. Structure of Class B GPCRs: new horizons for drug discovery. Br J Pharmacol. 2014 Jul;171(13):3132-45. doi: 10.1111/bph.12689. PMID:24628305 doi:http://dx.doi.org/10.1111/bph.12689
